Zhejiang DiAn Diagnostics Co (300244) - Net Assets
Based on the latest financial reports, Zhejiang DiAn Diagnostics Co (300244) has net assets worth CN¥8.66 Billion CNY (≈ $1.27 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.08 Billion ≈ $2.06 Billion USD) and total liabilities (CN¥5.41 Billion ≈ $792.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang DiAn Diagnostics Co tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.66 Billion |
| % of Total Assets | 61.54% |
| Annual Growth Rate | 40.11% |
| 5-Year Change | 15.09% |
| 10-Year Change | 237.97% |
| Growth Volatility | 79.78 |
Zhejiang DiAn Diagnostics Co - Net Assets Trend (2008–2025)
This chart illustrates how Zhejiang DiAn Diagnostics Co's net assets have evolved over time, based on quarterly financial data. See Zhejiang DiAn Diagnostics Co defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang DiAn Diagnostics Co (2008–2025)
The table below shows the annual net assets of Zhejiang DiAn Diagnostics Co from 2008 to 2025. For live valuation and market cap data, see Zhejiang DiAn Diagnostics Co market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.60 Billion ≈ $1.26 Billion |
-1.86% |
| 2024-12-31 | CN¥8.77 Billion ≈ $1.28 Billion |
-11.49% |
| 2023-12-31 | CN¥9.90 Billion ≈ $1.45 Billion |
+4.24% |
| 2022-12-31 | CN¥9.50 Billion ≈ $1.39 Billion |
+27.10% |
| 2021-12-31 | CN¥7.48 Billion ≈ $1.09 Billion |
+24.00% |
| 2020-12-31 | CN¥6.03 Billion ≈ $882.20 Million |
+17.33% |
| 2019-12-31 | CN¥5.14 Billion ≈ $751.88 Million |
+9.26% |
| 2018-12-31 | CN¥4.70 Billion ≈ $688.18 Million |
+59.59% |
| 2017-12-31 | CN¥2.95 Billion ≈ $431.21 Million |
+15.75% |
| 2016-12-31 | CN¥2.55 Billion ≈ $372.55 Million |
+140.45% |
| 2015-12-31 | CN¥1.06 Billion ≈ $154.94 Million |
+50.86% |
| 2014-12-31 | CN¥701.84 Million ≈ $102.70 Million |
+18.99% |
| 2013-12-31 | CN¥589.81 Million ≈ $86.31 Million |
+11.85% |
| 2012-12-31 | CN¥527.32 Million ≈ $77.16 Million |
+10.54% |
| 2011-12-31 | CN¥477.04 Million ≈ $69.81 Million |
+198.30% |
| 2010-12-31 | CN¥159.92 Million ≈ $23.40 Million |
+44.96% |
| 2009-12-31 | CN¥110.32 Million ≈ $16.14 Million |
+296.04% |
| 2008-12-31 | CN¥27.86 Million ≈ $4.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang DiAn Diagnostics Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42465.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.89 Billion | 60.37% |
| Other Components | CN¥2.55 Billion | 39.63% |
| Total Equity | CN¥6.44 Billion | 100.00% |
Zhejiang DiAn Diagnostics Co Competitors by Market Cap
The table below lists competitors of Zhejiang DiAn Diagnostics Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CBIZ Inc
NYSE:CBZ
|
$1.67 Billion |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
$1.67 Billion |
|
Inox Wind Limited
NSE:INOXWIND
|
$1.67 Billion |
|
Henan Lingrui Pharmaceutical Co Ltd
SHG:600285
|
$1.67 Billion |
|
Grand City Properties SA
F:GYC
|
$1.67 Billion |
|
PHARVARIS N.V. EO -12
F:9EN
|
$1.67 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
$1.67 Billion |
|
Parade Technologies Ltd
TWO:4966
|
$1.67 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang DiAn Diagnostics Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,564,302,204 to 6,442,461,924, a change of -121,840,280 (-1.9%).
- Net income of 44,052,664 contributed positively to equity growth.
- Dividend payments of 255,796,944 reduced retained earnings.
- Other comprehensive income decreased equity by 386,143,472.
- Other factors increased equity by 476,047,472.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥44.05 Million | +0.68% |
| Dividends Paid | CN¥255.80 Million | -3.97% |
| Other Comprehensive Income | CN¥-386.14 Million | -5.99% |
| Other Changes | CN¥476.05 Million | +7.39% |
| Total Change | CN¥- | -1.86% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang DiAn Diagnostics Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 177.32x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.10 | CN¥18.24 | x |
| 2009-12-31 | CN¥0.40 | CN¥18.24 | x |
| 2010-12-31 | CN¥0.45 | CN¥18.24 | x |
| 2011-12-31 | CN¥1.15 | CN¥18.24 | x |
| 2012-12-31 | CN¥1.06 | CN¥18.24 | x |
| 2013-12-31 | CN¥1.20 | CN¥18.24 | x |
| 2014-12-31 | CN¥1.40 | CN¥18.24 | x |
| 2015-12-31 | CN¥1.91 | CN¥18.24 | x |
| 2016-12-31 | CN¥3.81 | CN¥18.24 | x |
| 2017-12-31 | CN¥4.31 | CN¥18.24 | x |
| 2018-12-31 | CN¥6.72 | CN¥18.24 | x |
| 2019-12-31 | CN¥6.42 | CN¥18.24 | x |
| 2020-12-31 | CN¥7.57 | CN¥18.24 | x |
| 2021-12-31 | CN¥9.42 | CN¥18.24 | x |
| 2022-12-31 | CN¥11.94 | CN¥18.24 | x |
| 2023-12-31 | CN¥12.10 | CN¥18.24 | x |
| 2024-12-31 | CN¥10.72 | CN¥18.24 | x |
| 2025-12-31 | CN¥10.31 | CN¥18.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang DiAn Diagnostics Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.44%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 2.24x
- Recent ROE (0.68%) is below the historical average (13.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 27.15% | 3.70% | 1.61x | 4.57x | CN¥4.16 Million |
| 2009 | 16.29% | 6.52% | 1.47x | 1.70x | CN¥6.63 Million |
| 2010 | 21.37% | 9.44% | 1.47x | 1.54x | CN¥17.24 Million |
| 2011 | 9.09% | 8.75% | 0.80x | 1.29x | CN¥-4.22 Million |
| 2012 | 11.82% | 8.52% | 1.00x | 1.39x | CN¥9.28 Million |
| 2013 | 14.93% | 8.48% | 1.25x | 1.41x | CN¥28.43 Million |
| 2014 | 18.22% | 9.33% | 1.20x | 1.62x | CN¥56.20 Million |
| 2015 | 18.86% | 9.41% | 0.81x | 2.47x | CN¥82.11 Million |
| 2016 | 12.59% | 6.87% | 0.67x | 2.74x | CN¥53.99 Million |
| 2017 | 14.86% | 6.99% | 0.68x | 3.14x | CN¥114.40 Million |
| 2018 | 10.57% | 5.58% | 0.65x | 2.90x | CN¥21.01 Million |
| 2019 | 8.72% | 4.11% | 0.79x | 2.70x | CN¥-51.10 Million |
| 2020 | 17.09% | 7.54% | 0.86x | 2.64x | CN¥333.15 Million |
| 2021 | 19.91% | 8.89% | 0.84x | 2.67x | CN¥578.69 Million |
| 2022 | 19.26% | 7.07% | 0.96x | 2.83x | CN¥689.38 Million |
| 2023 | 4.06% | 2.29% | 0.75x | 2.37x | CN¥-449.17 Million |
| 2024 | -5.44% | -2.93% | 0.77x | 2.40x | CN¥-1.01 Billion |
| 2025 | 0.68% | 0.44% | 0.70x | 2.24x | CN¥-600.19 Million |
Industry Comparison
This section compares Zhejiang DiAn Diagnostics Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,741,258,786
- Average return on equity (ROE) among peers: 24.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang DiAn Diagnostics Co (300244) | CN¥8.66 Billion | 27.15% | 0.62x | $1.67 Billion |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $406.61 Million |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $742.36 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $2.53 Billion | 14.31% | 0.13x | $505.18 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.17 Billion |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About Zhejiang DiAn Diagnostics Co
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated… Read more